PTO/SB/08b (08-08)

Approved for use through 09/30/2008 OMB 0651-0031

Considered

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for form 1449/PTO Application Number 10/588,425-Conf. #5100

INFORMATION DISCLOSURE Filing Date June 6, 2007 STATEMENT BY APPLICANT First Named Inventor Todd C. Zankel Art Unit 1657 (Use as many sheets as necessary) Examiner Name Kailash C. Srivastava Sheet of Attorney Docket Number 30610/39385A

U.S. PATENT DOCUMENTS Document Number Evaminer Pages, Columns, Lines, Where Publication Date Name of Patentee or Number-Kind Code<sup>2</sup> ( If know evant Passages or Relevant Initiale\* MM-DD-YYYY Applicant of Cited Document Figures Appear

FOREIGN PATENT DOCUMENTS Foreign Patent Document Publication Examiner Pages, Columns, Lines, Name of Patentee or Date Initials: No Where Relevant Passay Country Code<sup>3</sup>-Number<sup>4</sup>-Kind Code<sup>5</sup> (#known) Applicant of Cited Document MM-DD-YYYY Or Relevant Figures Appear Examiner Date Signature

\*EXAMINES: Initial If reference consistently whether or not attention is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered notice copy of this form with next commerce consistent of applicant. \*Applicant's unique citation designation number (opticinal). \*See Kinds Codes of USPTO Patent Documents at www.usdot.gov or NPEP 10.1. \*Ener cince the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the two-lefter code (WPO States) of 51.0. \*Fee from the issued the decomment. by the issued the decomment of 51.0. \*Fee from the issued the decomment. by the issued the dec Japanese patent documents, the indication of the year of the rispn of the Emperor must precede the septiment of the patent document by the indication of the year of the rispn of the Emperor must precede the septiment of the patent document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a choick mark here if English language

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т	
		Supplementary Partial European Search Report for corresponding European Application No. EP05722947, dated July 16, 2008.	T	
		AMALFITANO et al., "Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: Results of a phase I/II clinical trial," Genetics in Medicine, 3:132-138 (2001).	T	
			$\pm$	

		4
Examiner /Kailash C. Srivastava/	Date Considered 06/17/2010	7
	Considered   UU/11/2U1U	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if Env ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /KS/